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Prostate cancer is the most common nonaskin cancer in men in the United States and the secaond leading cause of cancer death after lung cana
cer.1,2 In Jordan, prostate cancer is the third most coma
mon cancer in men, after lung and bladder cancers, with 
incidence of 5.6 per 100 000 men in the year 2001.3 
The incidence of prostate cancer increased dramatically 
in the mida1980s due to the introduction of PSA as a 
screening method.4 The incidence peaked in 1992 and 
has since declined. PSA was first introduced in 1979.5a7 
PSA levels have been used in screening large populaa
tions of men for prostate cancer and have been shown to 
be useful.8 The standard reference range of PSA is 0a4.0 
ng/mL. A cutoff 4.0 ng/mL has a sensitivity of 67.5% 
to 80%. The sensitivity can be increased by lowering 
the cutoff value, so a value of 2.5 ng/mL is sometimes 
suggested, but this will increase the number of unneca
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BACKGROUND AND OBJECTIVES: prostate-specific antigen (psa) and the psa ratio are good screening tests 
for prostate carcinoma. the significance of psa may be different from one ethnic group to another. radiologic 
findings may be helpful in detecting prostate carcinoma. 
METHODS: We reviewed the findings of 348 prostate biopsies performed in a 4-year period. of these, 278 cases 
were performed under ultrasound guidance and 70 were performed transrectally under digital guidance. psa, 
psa ratio, Gleason score and radiology findings were determined.
RESULTS: forty-three percent of the cases were diagnosed as having adenocarcinoma. the mean age for cancer 
patients was 68.4 years. the mean psa level for patients with carcinoma was 23.4 ng/ml compared to 11.2 
ng/ml for benign cases. carcinoma occurred in 11% (psa <4 ng/ml); 48.7% (psa=4-10 ng/ml); 50.6% (psa= 
10-30 ng/ml); 72% (psa >30 ng/ml). the psa ratio for cancer cases was 9.9% compared to 13.7% for benign 
cases. the average Gleason score for all cancers was 7 of 10. there was no relationship between psa level and 
Gleason score. the higher the Gleason score, the higher the percentage of carcinoma present in the cores. most 
of the carcinomas (100/122) showed hypoechoic areas on ultrasound exam, while heterogeneous areas favored 
a benign lesion in 54/76, with a sensitivity of 82% and specificity of 38%.
CONCLUSIONS AND IMPLICATIONS: the higher the psa, the greater the chance of having cancer. psa has 
a low positive predictive value for prostate carcinoma. twenty-eight percent of psa >30 can be attributed to 
benign conditions. a psa ratio <10 is suggestive of carcinoma. a radiologic finding of a hypoechoic lesion is a 
sensitive tool for detecting prostate carcinoma, but its specificity is low.
essary biopsies.9a11 In 2004, Thompson et al reported 
on the results of the Prostate Cancer Prevention Trial 
(PCPT), suggesting that prostate cancer detection rates 
were 24% and 27% for PSA levels of 2.1a3 ng/mL and 
for PSA levels of 3.1a4 ng/mL, respectively. This suga
gests that a significant number of men with PSA levels 
of 2a4 ng/mL have prostate carcinoma and should be 
counseled regarding prostate biopsy.12,13 The specifica
ity of PSA at levels greater than 4.0 ng/mL is 60% to 
70%. Specificity can be improved by using ageaadjusted 
values, PSA velocity, PSA density and PSA ratios (free 
PSA/total PSA). A PSA velocity of 0.75 ng/mL or 
greater per year was suggestive of cancer (72% sensitiva
ity, 95% specificity), but three PSA values are needed to 
calculate the PSA velocity.8,14 PSA density is defined as 
the total serum PSA divided by the volume of prostate 
as measured by a transrectal ultrasound. This was based 
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on the fact that most of PSA is produced by a trana
sitional zone of the prostate where BPH takes place. 
Cancer cells produce more PSA than benign cells per 
unit volume, which serves to increase PSA density. A 
cutoff value of 0.15 has been widely used.8,15 The ratio 
of free PSA to total PSA is also used to increase PSA 
specificity. Generally, a biopsy is recommended for a 
PSA ratio less than 10% and is not necessary for a ratio 
>25%.16 Transrectal ultrasound was first introduced in 
1970s by Watanabe et al. The greatest impact of trana
srectal ultrasound is its role in detecting small confined 
prostate cancer, but there are many benign conditions 
which decrease its specificity.17 A hypoechoic lesion on 
transrectal ultrasound is suspicious.13 Significant racial 
differences have been noted among ethnic groups. For 
example, PSA values were higher in AfricanaAmericans 
than in white Americans.18 On the other hand, a study 
of PSA levels in Asian men found a lower range of PSA 
levels in the population.19 It is known that Africana
American men have one of the highest prostate cancer 
rates worldwide, while Asian mean have among the 
lowest rates of prostate cancer worldwide.18
METHODS
Three hundred fortyaeight prostate biopsies were pera
formed at First Medical Laboratory during the period 
from January 2000 to September 2004. The biopsies 
were all taken from both prostate lobes and submitted 
in two designated containers as right and left prostate 
lobes. Three to four cores were taken from each side 
on average. Of these, 70 biopsies were performed trana
srectally without ultrasound guidance and 278 were 
performed under ultrasound guidance. Records of the 
PSA and PSA ratio were available for all cases. All bia
opsies were obtained and examined by one pathologist 
(HAF). A Gleason score was recorded on all prostate 
carcinoma cases.
RESULTS
Of the 348 cases, 150 (43%) cases were diagnosed as 
having adenocarcinoma. The mean age for prostate 
adenocarcinoma cases was 68.4 years (range, 45a90 
years) and 64.6 years for benign cases (range, 28a81 
years) (P>.05). The detection rate for carcinoma was 
44% (122/278) under ultrasound guidance and 40% 
(28/70) without radiologic assistance. The right and 
the left lobes had an almost equal chance of having ada
enocarcinoma. In 86 of the 150 cases diagnosed with 
cancer, cores from both lobes showed carcinoma. In 31 
cases, carcinoma was present in the right side alone, and 
in 33 cases carcinoma was present in the left side alone. 
Eight cases were diagnosed with atypical glands. Two of 
these 8 cases had a repeat biopsy in 2 years and proved 
to have carcinoma. 
 The average PSA for patients with carcinoma was 
23.4 ng/mL compared to 11.2 ng/mL for benign cases 
(P<.001). The average PSA for “atypical glands” was 19.4 
ng/mL. When serum PSA was less than 4.0 ng/mL, 3 
(of 28 patients) (11%) were diagnosed as having carcia
noma. When serum PSA was between 4.0a10.0 ng/mL, 
48.7% were proved to have carcinoma. When PSA was 
between 10a30 ng/mL, 50.6% were proved to have carcia
noma. When PSA was over 30 ng/mL, 72% were proved 
to have carcinoma (P<.00001). The PSA for different 
benign causes also showed different PSA levels: PSA 
was 12.0 ng/mL on average for prostatitis, 10 ng/mL for 
hyperplasia, 13.0 ng/mL for prostatitis and hyperplasia, 
and 4.8 ng/mL for completely normal cases. The PSA 
ratio was 9.9% for cancer cases, 13.7% for beniggn cases, 
and 10.5% for atypical cases. The PSA ratio for differa
ent types of benign causes was inflammation in 14.3%, 
hyperplasia in 9.9%, hyperplasia and inflammation in 
15.3%, and normal in 17.5%.
The average Gleason score for all cancers was 7 out 
of 10. There was no relationship between PSA and 
Gleason score. However, there was a strong relationship 
between Gleason score and percentage of carcinoma 
that was present in the cores. The average percentage of 
carcinoma seen in the cores in all patients was 52%. The 
higher the Gleason score, the higher the percentage of 
carcinoma that was present in the cores (P<.00001). 
The chiasquare test showed a significant relationship 
between the radiologic findings and the presence of cara
cinoma. Most of the carcinoma suspected on transrectal 
biopsies (100/122) showed hypoechoic areas (Figures 
1a and 1b), while heterogeneous areas favored a bea
nign lesion in 54/76 (P<.0002) (Figures 2a and 2b). 
However, this finding had a sensitivity of 82% and a 
specificity of 38%. Other radiologic findings of stromal 
nodules were also seen and were usually present in the 
transitional zone (Figures 3a and 3b).
DISCUSSION
Prostate adenocarcinoma is one of the most common 
cancers in Jordan.3 Early detection of prostate cancer 
is a major concern, and every effort should be made to 
find a reliable screening method. Several screening tools 
are available currently, including the digital rectal exam, 
transrectal ultrasound, and serum PSA. The PSA sea
rum marker is an excellent screening test for prostatic 
adenocarcinoma. The higher the serum PSA, the greata
er the chance of having cancer. However, serum PSA is 
not specific for prostate carcinoma.8 
In our study, we showed that 11% of patients with 
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Figure 1a. Non-homogenous echopattern with suspicious right-
sided hypoechoic lesion (arrow).
Figure 1b. Whole mount of prostate resection (hematoxylin-
eosin, normal size).
Figure 2a. Heterogenous echopattern. Figure 2b. Histological specimen showing benign prostatic 
hyperplasia (hematoxylin-eosin, ×50).
Figure 3a. Stromal nodules in the transitional zone (arrows). Figure 3b. Histological specimen showing stromal nodule 
(hematoxylin-eosin, ×50).
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a serum PSA <4.0 ng/mL have prostate adenocarcia
noma. In comparable studies in the West, a PSA level 
<4.0 ng/mL is associated with a 15% chance of hava
ing cancer.12 This slight decrease may be because PSA 
is inversely related to body mass index.20 However, in 
our study, patients with PSA levels between 4a10 ng/
mL had a 48.7% chance of having cancer, and patients 
with a serum PSA between 10a30 ng/mL had a 50% 
chance of having carcinoma, while for those with high 
PSA (PSA >30 ng/mL), the chance of having cancer 
was 72%. That means that benign prostatic conditions 
account for 28% of biopsies in patients with very high 
PSA (>30 ng/mL). In the West, studies showed that 
a serum PSA level between 4.0a10.0 ng/mL was asa
sociated with 25% chance of having prostate cancer.21 
However, 70% of patients with PSA serum levels of 10a
39 ng/mL, will have carcinoma.21
The PSA ratio is another good indicator for prostate 
carcinoma. In the West, a ratio of 10% or less is consida
ered “very suggestive” of carcinoma.16 In our study, the 
average PSA level in carcinoma was 23.4 ng/mL, with 
an average PSA ratio of 9.9%. In the West, a study by 
Tanguay showed that the average PSA ratio for carcia
noma is 14.2%.22 In Jordan, a ratio of less than 10% is 
considered “very suggestive” of carcinoma. 
Our study showed that radiological findings of a hya
poechoic lesion, as an indicator for carcinoma, is a sensia
tive tool for detecting prostate carcinoma (82%), but its 
specificity is low (38%). A study performed by Sheth et 
al reported that transurethral ultrasound has 55% sena
sitivity and 37% specificity for prostate cancer.23 Other 
conditions that may mimic carcinoma radiologically are 
granulomatous inflammation, chronic inflammation 
and infarction.24,25 Transrectal prostate biopsy without 
radiologic assistance carries a detection rate comparable 
to radiologic assistance if 10 cores or more taken as 
shown by our study. 
In summary, PSA is very useful for screening of 
prostate cancer in Jordan. Our PSA values are not difa
ferent from those in the West. Using the PSA ratio is 
of further help in defining higharisk cases. Radiological 
findings are helpful in pointing to the best biopsy sites. 
However, taking biopsies without radiological assisa
tance carries a comparable detection rate. 
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